

Oncology Today with Dr Neil Love: Current and Future Treatment Strategies for Advanced Ovarian Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. A study presented by Mirza and colleagues at ASCO 2020 evaluating an individualized starting dose versus a fixed starting dose of niraparib in the PRIMA study demonstrated which of the following outcomes?**
 - a. Significantly lower progression-free survival (PFS) with individualized doses
 - b. Less reported thrombocytopenia with individualized doses**
- 2. Results from the JAVELIN Ovarian 100 trial investigating avelumab in combination with chemotherapy and/or after chemotherapy versus chemotherapy alone for patients with previously untreated advanced ovarian cancer demonstrated which of the following outcomes on the avelumab treatment arms?**
 - a. A significant improvement in PFS
 - b. No significant improvement in PFS**
- 3. What did the 5-year follow-up results from the Phase III SOLO-1 study demonstrate regarding PFS with maintenance olaparib compared to placebo for patients with previously untreated advanced ovarian cancer and a BRCA mutation?**
 - a. No statistically significant difference between the arms
 - b. Significant reduction in the risk of disease progression with olaparib**
 - c. Significant reduction in the risk of disease progression with placebo
- 4. Which of the following is the molecular target of the antibody-drug conjugate mirvetuximab soravtansine?**
 - a. Folate receptor alpha**
 - b. PD-L1 (programmed death-ligand 1)
 - c. Tissue factor
 - d. PARP